Cell Line Development Market Size, Share, Analysis, Growth & Forecast (2022-2028)

According to a new report published by UnivDatos Markets Insights, the Cell Line Development market was valued at USD 4.5 billion in 2021 & is expected to grow at a CAGR of 10.0% from 2022-2028. The analysis has been segmented into Cell Line (Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line); Product (Reagents and Media, Equipment, Finished Cells, and Others); Source (Mammalian Cell Line, Non-mammalian Cell Line); and Application (Recombinant Protein Expression, Hybridomas Technology, Vaccine Production, Drug Discovery, Others); Region/Country.

Access sample report (including graphs, charts, and figures): https://univdatos.com/report/cell-line-development-market/get-a-free-sample-form.php?product_id=41799

The Cell Line Development market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities. This innovative report makes use of several analyses to get a closer outlook on the Cell Line Development market. The Cell Line Development market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth. Furthermore, this statistical market research repository examines and estimates the Cell Line Development market at the global and regional levels.

Key Market Dynamics

At present, with increasing awareness about the need and benefits of cell line development technology, spending on product development and R&D activities has increased globally. The key players actively investing in research and development into the cell line development landscape along with evolving favorable regulatory environment, and growing demand for monoclonal antibodies (mAbs) in developed economies are some of the major drivers for the increased penetration of cell line development devices among consumers, especially in the developed and developing countries. Additionally, the rising investments in biopharmaceutical R&D and product launches in the cell line development market are further contributing to the growth of the market. According to the National Institutes of Health (NIH), around USD 45 billion was granted for stem cell research in the fiscal year 2021. In addition, the increasing prevalence of chronic diseases and the need for more effective treatments, the demand for biologics has been growing rapidly. Moreover, the recent advancements in cell culture technology have made it easier and more efficient to develop cell lines, which has led to increased adoption of cell line development services, particularly in the pharmaceutical and biotechnology industries. For instance, Cadila Pharmaceuticals (Cadila) introduced NuPTH, a teriparatide biologic, and Cadalimab, a similar biologic to the auto-immune treatment adalimumab, in the Indian market in October 2021

Click here to view the Report Description & TOC https://univdatos.com/report/cell-line-development-market/

COVID-19 Impact

The COVID-19 pandemic has had a positive impact on the cell line development market due to the rising demand for COVID-19 therapies and vaccines, the cell line development market has been significantly affected by the COVID-19 pandemic. Adding to this, the pandemic has increased research and development efforts to create new COVID-19 vaccines and treatments. Therefore, a greater demand for high-quality cell lines that can be utilized in clinical trials and preclinical research.

The global Cell Line Development market report is studied thoroughly with several aspects that would help stakeholders in making their decisions more curated.

·        By cell line, the market is segmented into recombinant, hybridomas, continuous cell line, and primary cell line. Amongst these, the recombinant segment dominated the market in 2021.

·        On the basis of product, the market is segmented into reagents and media, equipment, finished cells, and others. Amongst these, the reagents and media segment are expected to grow with a significant CAGR during the forecast period.

·        Based on source, the market is segmented into mammalian cell line and non-mammalian cell line. Among these, the mammalian cell line captured the majority share of the cell line development market in 2021.

·        By application, the market is segmented into recombinant protein expression, hybridomas technology, vaccine production, drug discovery, and others. Recombinant protein expression are expected to grow with a significant CAGR during the forecast period.

Have a Look at the Chapters https://univdatos.com/report/cell-line-development-market/get-a-free-sample-form.php?product_id=41799

Cell Line Development Market Geographical Segmentation Includes:

·        North America (U.S., Canada, and the Rest of North America)

·        Europe (Germany, U.K., France, Italy, Spain, Rest of Europe)

·        Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific)

·        Rest of the World

Asia-Pacific is expected to grow with a significant CAGR during the forecast period due to the growing adoption of CRISPR technology in agriculture and animal breeding, the rising prevalence of genetic disorders, and increased investments in gene editing research. In addition, market expansion in developing nations is being driven by rising government investments in research and development and granted patents for these technologies to develop novel treatments. For instance, the Dublin-based ERS Genomics granted a CRISPR-Cas9 patent to the Japanese biotech company Setsuro Tech in March 2021. With the assistance of these trend-setting innovations, the organization is creating cell and creature models

Competitive Landscape

The degree of competition among prominent global companies has been elaborated by analyzing several leading key players operating worldwide. The specialist team of research analysts sheds light on various traits such as global market competition, market share, most recent industry advancements, innovative product launches, partnerships, mergers, or acquisitions by leading companies in the Cell Line Development market. The major players have been analyzed by using research methodologies such as Porter’s Five Forces Analysis for getting insight views on global competition.

Recent Developments:

·        In July 2022, ProBioGen and Granite Bio collaborated to provide services for the development of cell lines and GMP manufacturing. Granite Bio’s most promising candidate for the treatment of autoimmune diseases and specific cancer indications is a novel monoclonal antibody. With the help of the DirectedLuck transposase.

·        In June 2022, FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation and a world-leading contract development and manufacturing organization (CDMO), announced the investment of USD 1.6 billion from FUJIFILM Corporation to enhance and expand its cell culture manufacturing services.

Key questions resolved through this analytical market research report include:

• What are the latest trends, new patterns, and technological advancements in the cell line development market?

• Which factors are influencing the cell line development market over the forecast period?

• What are the global challenges, threats, and risks in the cell line development market?

• Which factors are propelling and restraining the cell line development market?

• What are the demanding global regions of the cell line development market?

• What will be the global market size in the upcoming years?

• What are the crucial market acquisition strategies and policies applied by global companies?

• What are the descriptive profiles of key companies along with their SWOT analysis?

We understand the requirement of different businesses, regions, and countries, we offer customized reports as per your requirements of business nature and geography. Please let us know If you have any custom needs. 

Related Report

Solar Photovoltaic (PV) industry

Wearable Medical Devices Market

Electric Buses Market

Wearable Medical Devices Market